This erratum corrects the following:

Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022;72(1):57–77. doi:10.3322/caac.21704

In the aforementioned article, an error appears in the Head and Neck Radiation Therapy section. The text should read as follows:

“From 59.4% to 100% of patients with H&N cancer who were treated with RT or chemoradiotherapy (CRT) have OM, with SOM affecting approximately 65% of patients.^9,10 The incidence is influenced by tumor site, radiation field, radiation technique, and the use of concomitant chemotherapy. A meta-analysis of 12 prospective trials including 1373 H&N cancer patients reported the incidence of SOM in 2 cisplatin-based CRT protocols. In this meta-analysis, the incidence of SOM was 40% for the high-dose cisplatin protocol (once every 3-4 weeks, 2 cycles) and 75% for the low-dose cisplatin protocol (once a week, 4-7 cycles) (P = .0202).¹¹” It is noteworthy that there was a significant survival benefit (P = .0185) for the high-dose schedule.

The authors apologize for the error.

此勘误表更正了以下内容：

埃拉德 S，亚罗姆 N，扎迪克 Y，库滕-肖勒 M，索尼斯 ST。口腔粘膜炎和抗癌治疗口腔溃疡性粘膜毒性的范围扩大。加州癌症杂志。2022；72（1）：57-77。doi:10.3322/caac.21704

在上述文章中，头颈部放射治疗部分出现错误。案文应如下所示：

“在接受放疗或放化疗 (CRT) 治疗的 H&N 癌症患者中，有 59.4% 到 100% 的患者患有 OM，其中约 65% 的患者受到 SOM 的影响。^9,10发病率受肿瘤部位、放射野、放射技术和伴随化疗的使用影响。对 12 项前瞻性试验（包括 1373 名 H&N 癌症患者）的荟萃分析报告了 2 种基于顺铂的 CRT 方案中 SOM 的发生率。在这项荟萃分析中，高剂量顺铂方案的 SOM 发生率为 40%（每 3-4 周一次，2 个周期），低剂量顺铂方案（每周一次，4-7 个周期）的 SOM 发生率为 75% ) ( P = .0202)。¹¹ ”值得注意的是，有显着的生存益处（P = .0185) 用于高剂量方案。

作者为这个错误道歉。